non-small cell lung cancer
Conditions
Interventions
The experimental group :docetaxel and paraplatin
The control group :gemcitabine and paraplatin
Sponsors
The First Affiliated Hospital Of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Non-small cell lung cancer (not including compound small cell carcinoma), newly confirmed by histology or cytology; 2. Never received surgery, chemotherapy, biological therapy, and radiation therapy in newly diagnosed non-small cell lung cancer; 3. The investigators estimate the stage IIIB-IV patients with lung cancer that they can not be surgical resection. The stage IIIB: T1-4N3M0, T4N0-3M0; The stage IV?: T1-4N0-3M1; 4. The disease can be assessed, according to the Response Evaluation Criteria in Solid Tumor (RECIST1.1), there is a lesion with measurable single path. And its longest diameter is measured >=10mm by spiral CT; 5. The patients with COPD are diagnosed clearly. In their pulmonary function tests,after the patients inhaled bronchodilators, FEV1 / FVC =90g/L(without blood transfusion in 14days);(2)BIL45ml/min(Cockcroft-Gault formula); 7. More than 65 years old; PS score 0-2 points; the estimated survival time is more than 3months, and the patients can complete above 2 cycles of chemotherapy.
Exclusion criteria
Exclusion criteria: 1. Non-small cell lung cancer and compound small cell carcinoma,newly confirmed by histology or cytology; 2. The newly diagnosed non-small cell lung cancer have ever received surgery, chemotherapy, biological therapy, and radiation therapy; 3. The stage IIIA patients with lung cancer are estimated that they can be with surgical resection by the investigators, or the patients in the stage IA, IB, IIA, IIB; 4. The disease can not be assessed, according to the Response Evaluation Criteria in Solid Tumor (RECIST1.1), there is a lesion with measurable single path.And its longest diameter is measured =90g/L(without blood transfusion in 14days);(2)BIL45ml/min (Cockcroft-Gault formula); 8. Less than 65 years old; PS score more than 2points; the estimated survival time is less than 3 months, and the patients can not complete above 2 cycles of chemotherapy; 9. The vital organs or the system of the patients exist serious primary disease; 10. The patients with mental or physical disabilities; 11. The patients with hepatitis A, hepatitis B, AIDS, tuberculosis and other infectious diseases or connective tissue disease in the active stage; 12. The patients with serious infections, especially lung infection; 13. The patients who participate in other clinical trials; 14. Any other situations not suitable for this study determined by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest CT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood-routine;Urine-routine;Stool-routine;Blood biochemical examination;Blood tumor marker;Pulmonary function test;Electrocardiogram;Abdomen B ultrasonography;Evaluation of Adverse Drug Reactions;Al - antitrypsin concentration; | — |
Countries
China
Contacts
Public ContactYinYin Qin
Outcome results
None listed